Figure 7
Figure 7. A Db-SAP tetramer is associated with reversible hepatotoxic effects. (A) Administration of gpK1S-SAP tetramer to C57BL/6J mice (n = 5 per group) results in temporary weight loss. The top panel depicts the mean percentage change over time versus pretreatment body weights; the bottom panel displays mean body weights. Only the weight loss in the high dose group was significant (*P < .05 by ANOVA vs treatment with nontoxic tetramer) at the indicated time points. (B) Administration of gpK1S-SAP causes an increase in serum ALT that resolves by 12 days after administration. Serum bilirubin was unaffected by treatment. In control mice injected with the nontoxic tetramer, serum biochemical values at all points were consistent with published reference ranges (ALT: 44-87 IU/L; creatinine: 42.4-97.2 μM [0.48-1.1 mg/dL]; and total bilirubin: 5.1-13.7 μM [0.3-0.8 mg/dL]).35

A Db-SAP tetramer is associated with reversible hepatotoxic effects. (A) Administration of gpK1S-SAP tetramer to C57BL/6J mice (n = 5 per group) results in temporary weight loss. The top panel depicts the mean percentage change over time versus pretreatment body weights; the bottom panel displays mean body weights. Only the weight loss in the high dose group was significant (*P < .05 by ANOVA vs treatment with nontoxic tetramer) at the indicated time points. (B) Administration of gpK1S-SAP causes an increase in serum ALT that resolves by 12 days after administration. Serum bilirubin was unaffected by treatment. In control mice injected with the nontoxic tetramer, serum biochemical values at all points were consistent with published reference ranges (ALT: 44-87 IU/L; creatinine: 42.4-97.2 μM [0.48-1.1 mg/dL]; and total bilirubin: 5.1-13.7 μM [0.3-0.8 mg/dL]).35 

Close Modal

or Create an Account

Close Modal
Close Modal